Verge Genomics, a drug discovery company utilizing machine learning to develop new therapeutics, raised $32 million in Series A financing led by DFJ. New biotech investors WuXi AppTec’s Corporate Venture Fund, ALS Investment Fund, Agent Capital, and OS Fund also participated in the round.
Founded in 2015, Verge uses machine learning, neuroscience, and experimental biology to accelerate drug discovery. According to the company, it has developed lead therapeutic programs in ALS and Parkinson’s disease while establishing partnerships with two pharmaceutical companies. Verge also invested heavily in the creation of its proprietary datasets, generating one of the field’s largest and most comprehensive databases of ALS and Parkinson’s disease patient genomic data through partnerships with a dozen top-tier academic and government organizations.